Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Movers & Shakers

Movers & Shakers DOI:10.1002/cind.8512_4.x PEOPLE German therapeutic antibody developer, SciRhom At Mirati Therapeutics, a US-based clinical-stage has added Jürgen Reeß as CMO. The company targeted oncology company, Daniel Faga will step is also establishing a board of directors which down from his role as Executive Vice President will include Carl Blobel, Wolfgang Baiker and and COO. In addition, Joseph Leveque will step Hans-Ulrich Rabe. In January 2022, Andreas down from his role as Executive Vice President and Jenne, currently SciRhom’s CBO, will move from CMO. The company will establish the role of CFO management and join the board. to support the expansion of its commercialisation Nicolas Gaudenzio has been capabilities and expanding portfolio. appointed CSO of ex vivo Clinical stage immune-oncology company SOTIO clinical testing specialist Biotech has announced the addition of Alise Bayer has announced Christoph Koenen will be Genoskin. Gaudenzio will Reicin, Josep Tabernero and Anthony Tolcher its new global head of clinical development and lead Genoskin’s existing R&D to its strategic advisory board. Reicin was most operations within R&D at its Pharmaceuticals team in immunology and recently President, global clinical development Division, effective 1 January 2022. Koenen joins data-oriented innovations, for Celgene, Tabernero is head of the medical Bayer from Otsuka Pharmaceutical, where he supporting the development of oncology department at the Vall d’Hebron most recently held the position of CMO. Before new offers and establishing the University Hospital, while Tolcher is CEO and this, he held multiple senior leadership positions company’s long-term scientific founder of NEXT Oncology. in clinical development at GlaxoSmithKline, Novo strategy. He will continue Nordisk, and Bristol Myers Squibb. to lead a research group at Cambridge, MA-based biotech firm Biogen has Inserm – the French National announced that head of R&D Alfred W. Sandrock, Alex Gorsky, currently Chairman and CEO of Institute of Health and Medical Jr will retire from the company at the end of Johnson & Johnson, will serve as Executive Research. 2021. During 23 years at Biogen, Sandrock, led Chairman and transition the CEO role to Joaquin the development of many of the Company’s Duato, currently Vice Chairman of the company’s most important and transformational therapies Executive Committee, effective 3 January 2022. in neurological diseases. Priya Singhal, Head Duato will also be appointed as a member of the of global safety and regulatory sciences, will company’s board of directors while Gorsky has become Head of R&D on an interim basis until a also been elected to Apple’s board of directors. permanent successor is identified. The winners of the EU Prize for Women At the general meeting of the International Innovators 2021 have been announced at the Association of Horticultural Producers (AIPH), European Innovation Council Summit in Brussels. Zhang Qixiang of the China Flower Association The prize is awarded to the most talented and Tim Edwards of the UK’s Horticultural Trade women entrepreneurs from across the EU and Association stepped down from their positions countries associated to Horizon Europe, who Robert MacLeod will step down as Vice Presidents. Taking their place are two have founded a successful company and brought as CEO of Johnson Matthey and leading industry figures – Zhou Jianping of the innovation to the market. The winners, who will from the Board. He will stay on China Flower Association and Leonardo Capitanio, each receive a €100,000 cash prize, included to support the transition President of ANVE, Italy’s National Association of Daphne Haim Langford from Israel: founder and process until the AGM in July, Nursery Stock Exporters. CEO of Tarsier Pharma, a company developing when he will retire. Liam disruptive medical solutions for the treatment Condon, above, replaces Bjorn Hansen, Executive Director of European and cure of autoimmune and inflammatory ocular MacLeod on 1 March 2022. He is Chemicals Agency (ECHA), is to leave his post diseases. currently a member of the at the end of March 2022. In other changes at board of management of Bayer ECHA, Deputy Executive Director and Director of Toxys, a biotech company based in Leiden, The AG and President of the crop submissions and interaction Jukka Malm is leaving Netherlands, has announced the creation of its science division and will be on 1 April 2022 and will be replaced by Mercedes scientific advisory board, recruiting Bob van de succeeded by Rodrigo Santos Viñas; Ofelia Bercaru will replace Jack de Bruijn Water, Clive Roper, Peter Boogaard, Giel Hendriks effective 1 January 2022. Santos as director of prioritisation and integration; and Torben Østerlund. Toxys was founded in 2014 is currently COO of the crop and Christel Musset will be replaced by Mike as a spin-off from the Leiden University Medical science division of Bayer and Rasenberg as director of hazard assessment. Center. It provides in vitro toxicity screening responsible for the global solutions to identify carcinogenic and other commercial operations of the Aditum Bio has appointed Stephen Kanes as hazardous properties of compounds for the company’s agriculture CEO of Ancora Bio, a portfolio company focused pharmaceutical, chemical, cosmetics and food business. on neuroscience, with a Phase 2 ready asset industry. The brief given to the board is to help in treatment-resistant depression. Kanes is guide the development of innovative animal-free a neuropsychiatrist, with a career in basic assays to ensure the safety of novel medicines neuroscience, clinical psychiatry, and neuroscience and other products for humans, and to accelerate drug development spanning more than 30 years. business growth to become an industry-leader in He was most recently CMO of Sage Therapeutics. chemical safety assessment. 14 12 | DECEMBER 2021 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Chemistry & Industry Wiley

Movers & Shakers

Chemistry & Industry , Volume 85 (12) – Dec 1, 2021
Download PDF
1 page

Loading next page...
 
/lp/wiley/movers-shakers-EJOsJ32UL5

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wiley
Copyright
© Society of Chemical Industry 2021
ISSN
0009-3068
eISSN
2047-6329
DOI
10.1002/cind.8512_4.x
Publisher site
See Article on Publisher Site

Abstract

DOI:10.1002/cind.8512_4.x PEOPLE German therapeutic antibody developer, SciRhom At Mirati Therapeutics, a US-based clinical-stage has added Jürgen Reeß as CMO. The company targeted oncology company, Daniel Faga will step is also establishing a board of directors which down from his role as Executive Vice President will include Carl Blobel, Wolfgang Baiker and and COO. In addition, Joseph Leveque will step Hans-Ulrich Rabe. In January 2022, Andreas down from his role as Executive Vice President and Jenne, currently SciRhom’s CBO, will move from CMO. The company will establish the role of CFO management and join the board. to support the expansion of its commercialisation Nicolas Gaudenzio has been capabilities and expanding portfolio. appointed CSO of ex vivo Clinical stage immune-oncology company SOTIO clinical testing specialist Biotech has announced the addition of Alise Bayer has announced Christoph Koenen will be Genoskin. Gaudenzio will Reicin, Josep Tabernero and Anthony Tolcher its new global head of clinical development and lead Genoskin’s existing R&D to its strategic advisory board. Reicin was most operations within R&D at its Pharmaceuticals team in immunology and recently President, global clinical development Division, effective 1 January 2022. Koenen joins data-oriented innovations, for Celgene, Tabernero is head of the medical Bayer from Otsuka Pharmaceutical, where he supporting the development of oncology department at the Vall d’Hebron most recently held the position of CMO. Before new offers and establishing the University Hospital, while Tolcher is CEO and this, he held multiple senior leadership positions company’s long-term scientific founder of NEXT Oncology. in clinical development at GlaxoSmithKline, Novo strategy. He will continue Nordisk, and Bristol Myers Squibb. to lead a research group at Cambridge, MA-based biotech firm Biogen has Inserm – the French National announced that head of R&D Alfred W. Sandrock, Alex Gorsky, currently Chairman and CEO of Institute of Health and Medical Jr will retire from the company at the end of Johnson & Johnson, will serve as Executive Research. 2021. During 23 years at Biogen, Sandrock, led Chairman and transition the CEO role to Joaquin the development of many of the Company’s Duato, currently Vice Chairman of the company’s most important and transformational therapies Executive Committee, effective 3 January 2022. in neurological diseases. Priya Singhal, Head Duato will also be appointed as a member of the of global safety and regulatory sciences, will company’s board of directors while Gorsky has become Head of R&D on an interim basis until a also been elected to Apple’s board of directors. permanent successor is identified. The winners of the EU Prize for Women At the general meeting of the International Innovators 2021 have been announced at the Association of Horticultural Producers (AIPH), European Innovation Council Summit in Brussels. Zhang Qixiang of the China Flower Association The prize is awarded to the most talented and Tim Edwards of the UK’s Horticultural Trade women entrepreneurs from across the EU and Association stepped down from their positions countries associated to Horizon Europe, who Robert MacLeod will step down as Vice Presidents. Taking their place are two have founded a successful company and brought as CEO of Johnson Matthey and leading industry figures – Zhou Jianping of the innovation to the market. The winners, who will from the Board. He will stay on China Flower Association and Leonardo Capitanio, each receive a €100,000 cash prize, included to support the transition President of ANVE, Italy’s National Association of Daphne Haim Langford from Israel: founder and process until the AGM in July, Nursery Stock Exporters. CEO of Tarsier Pharma, a company developing when he will retire. Liam disruptive medical solutions for the treatment Condon, above, replaces Bjorn Hansen, Executive Director of European and cure of autoimmune and inflammatory ocular MacLeod on 1 March 2022. He is Chemicals Agency (ECHA), is to leave his post diseases. currently a member of the at the end of March 2022. In other changes at board of management of Bayer ECHA, Deputy Executive Director and Director of Toxys, a biotech company based in Leiden, The AG and President of the crop submissions and interaction Jukka Malm is leaving Netherlands, has announced the creation of its science division and will be on 1 April 2022 and will be replaced by Mercedes scientific advisory board, recruiting Bob van de succeeded by Rodrigo Santos Viñas; Ofelia Bercaru will replace Jack de Bruijn Water, Clive Roper, Peter Boogaard, Giel Hendriks effective 1 January 2022. Santos as director of prioritisation and integration; and Torben Østerlund. Toxys was founded in 2014 is currently COO of the crop and Christel Musset will be replaced by Mike as a spin-off from the Leiden University Medical science division of Bayer and Rasenberg as director of hazard assessment. Center. It provides in vitro toxicity screening responsible for the global solutions to identify carcinogenic and other commercial operations of the Aditum Bio has appointed Stephen Kanes as hazardous properties of compounds for the company’s agriculture CEO of Ancora Bio, a portfolio company focused pharmaceutical, chemical, cosmetics and food business. on neuroscience, with a Phase 2 ready asset industry. The brief given to the board is to help in treatment-resistant depression. Kanes is guide the development of innovative animal-free a neuropsychiatrist, with a career in basic assays to ensure the safety of novel medicines neuroscience, clinical psychiatry, and neuroscience and other products for humans, and to accelerate drug development spanning more than 30 years. business growth to become an industry-leader in He was most recently CMO of Sage Therapeutics. chemical safety assessment. 14 12 | DECEMBER 2021

Journal

Chemistry & Industry – Wiley

Published: Dec 1, 2021

There are no references for this article.